Gilead Sciences (NASDAQ:GILD) provid For 2023, Gilead retains non-GAAP diluted EPS of between $6.60 and $7 on total product sales between $26 billion and $26.5 billion, both unchanged from the previous guidance.
Analysts polled by Capital IQ expected a normalized EPS of $6.84 on revenue of $26.73 billion.